Several chemotherapeutic drugs including doxorubicin, paclitaxel, gemcitabine, cisplatin, and melphalan have been used in preclinical studies in combination with NGR–TNF for targeted therapy against RMA lymphoma and WEHI-164 murine fibrosarcoma tumor bearing mice. The gene discussed is TNF; the disease is lymphoma.